A Single-Dose, Bioequivalence Study of FMXIN001 4 mg Microspheres Powder

Phase 1

Completed

• Conditions: Opioid Overdose
• Interventions: Combination Product: Nasus Pharma FMXIN001; Combination Product: Nasal Naloxone liquid spray

• Registration Number: NCT04713709
• Lead Sponsor: Nasus Pharma

Brief Summary

A Single-Dose, Bioequivalence Study of FMXIN001 4 mg Microspheres Nasal Powder.

Detailed Description

A comparison between FMXIN001 4 mg and Narcan® 4 mg/0.1 mL Nasal Spray under Fasting Conditions. A pharmacokinetic study in healthy volunteers

Study Timeline

• Study First Submitted: 2021-01-11
• Study First Submitted QC: 2021-01-14
• Study First Posted: 2021-01-19
• Study Start: 2021-01-31
• Primary Completion: 2021-03-30
• Study Completion: 2021-10-10
• Status Verified: 2022-04
• Last Update Submitted: 2022-04-25
• Last Update Posted: 2022-05-02

Recruitment & Eligibility

• Status: COMPLETED
• Sex: All
• Target Recruitment: 46

Inclusion Criteria

1. Healthy, non-smoking, male and female subjects, 18 years of age or older.

2. BMI ≥18 and ≤30 kg/m2.

3. Females may be of childbearing or non-childbearing potential:

   • Childbearing potential:

     o Physically capable of becoming pregnant

   • Non-childbearing potential:

     • Surgically sterile (i.e., both ovaries removed, uterus removed, or bilateral tubal ligation); and/or
     • Postmenopausal (no menstrual period for at least 12 consecutive months without any other medical cause).

4. Willing to use acceptable, effective methods of contraception.

5. Able to tolerate venipuncture.

6. Be informed of the nature of the study and give written consent prior to any study procedure.

Exclusion Criteria

• The following exclusion criteria will be assessed at screening (within 28 days prior to the first drug administration):

  1. Known history or presence of clinically significant neurologic, hematologic, endocrine, oncologic, pulmonary, immunologic, genitourinary, psychiatric, or cardiovascular disease or any other condition which, in the opinion of the Investigator, would jeopardize the safety of the subject or impact the validity of the study results.

  2. Known or suspected carcinoma.

  3. Known history or presence of hypersensitivity or idiosyncratic reaction to naloxone or any other drug substances with similar activity.

  4. Known history or presence of clinically significant lactose, galactose, or fructose intolerance.

  5. Presence of hepatic or renal dysfunction.

  6. Presence of nostril or septum piercing.

  7. Presence of abnormal nasal anatomy.

  8. Presence of hay fever/seasonal allergy/rhinitis.

  9. Presence of sinusitis.

  10. Presence of nasal symptoms (e.g., blocked and/or runny nose, nasal polyps).

  11. Presence of nasal septum ulcers or perforations, or nasal trauma within 30 days prior to drug administration.

  12. History of nasal surgery.

  13. History of malabsorption within the last year or presence of clinically significant gastrointestinal disease.

  14. History of atopic allergy (e.g., asthma, urticaria, eczematous dermatitis).

  15. Presence of a medical condition requiring regular medication (prescription and/or over-the-counter) with systemic absorption.

  16. History of drug or alcohol addiction requiring treatment.

  17. Any acute illness (e.g., cold/ rhinitis, acute infection) which is considered significant by the Investigator and that has not resolved within 7 days before the first drug administration.

  18. Positive test result for HIV, Hepatitis B surface antigen, or Hepatitis C antibody.

  19. Positive test result for urine drugs of abuse (amphetamines, barbiturates, benzodiazepines, cannabinoids, cocaine, methadone, opiates, phencyclidine, and tricyclic antidepressants) or urine cotinine.

  20. Difficulty fasting or consuming standard meals.

  21. Inability to communicate well with the Investigators and staff (i.e., language problem, poor mental development or impaired cerebral function).

  22. Use of tobacco or nicotine-containing products within 6 months prior to drug administration.

  23. Females who:

      • Have discontinued or changed the use of implanted, intrauterine, intravaginal, or injected hormonal contraceptives within 6 months prior to drug administration;
      • Have discontinued or changed the use of oral or patch hormonal contraceptives within 1 month prior to drug administration;
      • Are pregnant (serum hCG consistent with pregnancy); or
      • Are lactating.

  24. Donation or loss of whole blood (including clinical trials):

      • ≥50 mL and <500 mL within 30 days prior to drug administration;
      • ≥500 mL within 56 days prior to drug administration.

  25. Participation in a clinical trial that involved administration of an investigational medicinal product within 30 days prior to drug administration, or recent participation in a clinical investigation that, in the opinion of the Investigator, would jeopardize subject safety or the integrity of the study results.

  26. On a special diet within 30 days prior to drug administration (e.g., liquid, protein, raw food diet).

  27. Have had a tattoo or body piercing within 30 days prior to drug administration.

  28. Have clinically significant findings in vital signs measurements.

  29. Systolic blood pressure increase or decrease in value by more than 20 mmHg and/or diastolic blood pressure decrease in value by more than 10 mmHg from supine or sitting to standing position.

  30. Have clinically significant findings in a 12-lead ECG.

  31. Have clinically significant abnormal laboratory values.

  32. Have significant diseases.

  33. Have clinically significant findings from a physical examination.

  34. Use of any enzyme-modifying drugs known to induce/inhibit hepatic drug metabolism or alter gastrointestinal pH/movement (e.g., omeprazole, ranitidine) within 30 days prior to drug administration.

Study & Design

• Study Type: INTERVENTIONAL
• Study Design: CROSSOVER

Arm && Interventions

Group	Intervention	Description
FMXIN001 4 mg Naloxone microspheres powder,	Nasal Naloxone liquid spray	Naloxone powder nasal spray from Nasus Pharma, Israel
FMXIN001 4 mg Naloxone microspheres powder,	Nasus Pharma FMXIN001	Naloxone powder nasal spray from Nasus Pharma, Israel
Narcan® 4 mg/0.1 mL nasal spray	Nasus Pharma FMXIN001	Naloxone solution nasal spray from Adapt Pharma, Inc., USA
Narcan® 4 mg/0.1 mL nasal spray	Nasal Naloxone liquid spray	Naloxone solution nasal spray from Adapt Pharma, Inc., USA

Primary Outcome Measures

Name	Time	Method
Unconjugated naloxone in plasma - Tmax	0 to 8 hours post dose	Pharmacokinetic Parameters
Unconjugated naloxone in plasma- T half	0 to 8 hours post dose	Pharmacokinetic Parameters
Unconjugated naloxone in plasma - K el	0 to 8 hours post dose	Pharmacokinetic Parameters
Unconjugated naloxone in plasma - Cmax	0 to 8 hours post dose	Pharmacokinetic Parameters
Unconjugated naloxone in plasma - AUC	0 to 8 hours post dose	Pharmacokinetic Parameters

Secondary Outcome Measures

Name	Time	Method
12-Lead ECG	12 hours	Safety Monitoring
Blood pressure	12 hour post dose	Safety Monitoring: Vital signs
Pulse	12 hour post dose	Safety Monitoring: Vital signs
Nasal examination	23 hour	Safety Monitoring
Adverse events	0 to 24 hour post dose	Safety Monitoring
4-item NHANES Pocket Smell Test	24 hours post dose	Safety Monitoring

Trial Locations

Locations (1)

Pharma Medica Research Inc; 🇨🇦 Mississauga, Ontario, Canada